H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)

September 2, 2026 6:55 AM

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $120.00 price target on BridgeBio Pharma (NASDAQ: BBIO).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found